Novo Nordisk type 2 diabetes pill Rybelsus now has FDA approval for use as a first-line therapy, a change that enables the fast-growing product to reach an even larger group of patients in the ...

MISSISSAUGA, ON, June 9, 2026 /CNW/ - Novo Nordisk today announced the Canadian availability of an updated formulation of Rybelsus® (semaglutide tablets), a prescription medicine used by adults with ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Interest surrounding glucagon-like peptide 1 agonists (GLP-1), a class of type 2 diabetes drugs that help ...

The Food and Drug Administration approved Novo Nordisk’s Rybelsus for use as a first-line treatment for type 2 diabetes, the company announced Thursday. The drug, also known as semaglutide, is a ...

Rybelsus is a glucagon-like peptide receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The Food and Administration (FDA) ...

The Food and Drug Administration approved Novo Nordisk's oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes. The drug, called Rybelsus, is ...

Novo Nordisk NVO announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral semaglutide compared with placebo as an adjunct to standard of care for the ...

Novo Nordisk’s pill to treat diabetes can now be marketed for its cardiovascular benefits, following approval by European regulators. Rybelsus, an oral version of the semaglutide drug that is the main ...